Cofepris authorizes Pfizer’s paxlovid pill for emergency use in COVID treatment

The emergency use authorization is issued in a controlled manner and requires a prescription. (ARCHIVE)

Cofepris authorized the paxlovid treatment from the pharmaceutical company Pfizer for emergency use of COVID.

The medicine that combines nirmatrelvir and ritonavir in tablet presentation will be used to treat adult patients with mild or moderate COVID-19 and at risk of complications.

The authorization for emergency use is issued in a controlled manner and requires a medical prescription, considering the use and risk factors detailed in the authorization document to avoid misuse of this medication, self-medication and/or its irregular sale.

The two components of paxlovid work together to reduce hospitalization and mortality rates from this virus by up to 88%. The first, nirmatrelvir, inhibits a SARS-CoV-2 protein, preventing the virus from replicating; while the second, ritonavir, slows the breakdown of the drug to help it stay in the body longer.

This authorization for controlled emergency use is issued after the technical analysis carried out by specialized personnel from Cofepris, who examined the scientific evidence presented by the pharmaceutical company Pfizer SA de CV. Previously, experts from the National Committee for Science, Technology and Innovation in Public Health of the National Council for Science and Technology (Conacyt), and the New Molecules Committee of Cofepris, issued unanimous favorable opinions on paxlovid.

Evidence is based on the EPIC-HR randomized, double-blind, placebo-controlled clinical trial, which studied the treatment in people 18 years of age and older in more than 20 countries, including Mexico.

Leave a Comment